Thrombosis and Cancer: Case Series of 25 Patients
American Journal of Internal Medicine
Volume 5, Issue 4, July 2017, Pages: 61-66
Received: May 3, 2017; Accepted: May 10, 2017; Published: Jul. 6, 2017
Views 1981      Downloads 112
Authors
Said Kaddouri, Department of Internal Medicine, IbnSina Military Hospital, Marrakesh, Morocco
Zakaria Chahbi, Department of Internal Medicine, IbnSina Military Hospital, Marrakesh, Morocco
Ismail Essadi, Department of Medical Oncology, IbnSina Military Hospital, Marrakesh, Morocco
Hassan Qacif, Department of Internal Medicine, IbnSina Military Hospital, Marrakesh, Morocco
Mohamed Zyani, Department of Internal Medicine, IbnSina Military Hospital, Marrakesh, Morocco
Article Tools
Follow on us
Abstract
The objective of this paper is to describe the clinical and therapeutic characteristics of thrombosis associated with cancers in patients in charge of the internal medicine-oncology department of the Ibn Sina Military Hospital in Marrakech. This is a retrospective, descriptive and analytical study over a two-year period from January 2013 to December 2014. Among 158 patients with cancer, we identified 25 with thrombosis confirmed by imaging. Characteristics of the population of origin, incidence, risk factors for venous thromboembolic disease (VTE), diagnostic means, distribution of thrombosis, location and histological type of cancer and therapeutic strategy were analyzed. The mean age of our patients was 55.89 years, with female predominance (56% vs 44%). The incidence of venous thrombosis in our series is 15.8% (n = 25) of which 76% (n = 19) are isolated, 12% (n = 3) are on central venous catheter (CVC) and 12% (n = 3) are associated with pulmonary embolism. The lower limbs were the most affected (80.3%), with predominance on the left side. Bilateral involvement was found in 7% of cases. Thrombosis was indicative of cancer in 16% of patients (n = 4). While it complicated the development in 84% of the cases (n = 21). Risk factors for VTE were dominated by females (56%), metastases (64%), chemotherapy (80%), and the presence of a CVC (80%). Solid tumors were the most frequent 72% (n = 18) with predominantly digestive cancers (28%), pulmonary (16%), bladder (16%) and breast (12%). The most predominant histological type was adenocarcinoma in 44% (n = 11). The seven cases of malignant hemopathies are: four non-Hodgkin's lymphomas, two multiple myelomas and one case of chronic myeloid leukemia. The initial curative treatment as a relay used low molecular weight heparin in 92% of patients (n = 23). Unfractionated heparin was used in two patients with severe renal failure, the only ones receiving vitamin K antagonist maintenance therapy. Short-term outcomes were favorable in 92% (n = 23), two deaths Have been attributed to severe pulmonary embolism. Significant progress has been made in the context of cancer-related VTE. Nevertheless, there remains a considerable field of unresolved clinical issues. Numerous studies are underway and may lead to advances not only in the treatment of VTE associated with cancer but also in the treatment of the cancerous disease itself.
Keywords
Thrombosis, Cancer, Anticoagulants, Pulmonary Embolism
To cite this article
Said Kaddouri, Zakaria Chahbi, Ismail Essadi, Hassan Qacif, Mohamed Zyani, Thrombosis and Cancer: Case Series of 25 Patients, American Journal of Internal Medicine. Vol. 5, No. 4, 2017, pp. 61-66. doi: 10.11648/j.ajim.20170504.13
Copyright
Copyright © 2017 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
AA. Khorana. Malignancy, Thrombosis and Trousseau: the case for an eponym. Journal of Thrombosis and Haemostasis. 2003; (1): 2463-65.
[2]
R. Belhadj Chaidi, et al. Application des recommandations dans le traitement de la maladie thromboembolique veineuse chez les patients atteints de cancer: étude rétrospective sur 145 cas. Journal des Maladies Vasculaires (2013) 38, 185-192.
[3]
HK. Chew, T. Wun, D. Harvey, H. Zhou, RH. White. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006; 166: 458-64.
[4]
JT. Murchison, L. Wylie, DL. Stockton. Excess risk of cancer in patients with primary venous thromboembolism: a national, population-based cohort study. Br J Cancer 2004; 91: 92-5.
[5]
T. Sorensen, L. Mellemkjaer, J. Olsen, et al. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343: 1846-50.
[6]
D. Farge, P. Debourdeau, M. Beckers, et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost 2013; 11: 56–70.
[7]
J. Médioni, JP. Guastalla, L. Drouet. Thrombose veineuse et cancer du sein. Bull Cancer 2012; 99: 199-210.
[8]
HR. Buller, et al. Cancer and thrombosis: from molecular mechanisms to clinical presentations. J Thromb Haemost 2007; 5 (Suppl. 1): 246-54.
[9]
P. Girard, C. Raynaud, G. Meyer, F. Parent, B. Besse. Thrombose et cancer bronchique. Revue de Pneumologie clinique (2008) 64, 85-91.
[10]
A. Bertoïa, M.-T. Barrellier, V. NGuyen-Van, L. Berger, C. Le Hello. Incidence et distribution de 1026 thromboses veineuses des membres inférieurs diagnostiquées par écho-Doppler chez 3263 patients atteints de cancer. Journal des Maladies Vasculaires (2013) 38, 243-251.
[11]
AA. Khorana, et al. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 2005; 104 (12): 2822.
[12]
T. Wun, RH. White. Epidemiology of cancer-related venous thromboembolism. Best Pract Res Clin Haematol 2009; 22: 9-23.
[13]
G. Meyer, P. Girard. Maladie veineuse thromboembolique et cancer. Revue des Maladies Respiratoires Actualités (2016) 8, 489-496.
[14]
C. Martinez, AT. Cohen, L. Bamber, S. Rietbrock. Epidemiology of first and recurrent venous thromboembolism: a population-based cohort study in patients without active cancer. Thrombosis and Haemostasis 112. 2/2014.
[15]
M. Cushman, et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med 2004; 117: 19‑25.
[16]
M. Carrier, et al. Systematic review: the Trousseau syndrome revisited: should we screen extensively for cancer in patients with venous thromboembolism? Ann Intern Med 2008; 149: 323‑33.
[17]
C. Ay, D. Dunkler, C. Marosi, et al. Prediction of venous thromboembolism in cancer patients. Blood 2010; 116: 5377‑82.
[18]
C. Boccalon, P. Leger, D. Barcat, J. Guilloux, H. Boccalon. Thromboses veineuses des membres inférieurs et de la veine cave inférieure. EMC. Cardiologie. 11-730-A-10 (2004); 11p.
[19]
C.-M. Samama et al. Prévention de la maladie thromboembolique veineuse périopératoire et obstétricale. Annales Françaises d’Anesthésie et de Réanimation 24 (2005) 853–861.
[20]
M. Pavic, P. Debourdeau, M. Aletti, D. Farge-Bancel, H. Rousset. Maladie veineuse thromboembolique et cancer. Rev Med interne. 2006; (27): 313-322.
[21]
HE. Fuentes, AJ. Tafur, JA. Caprini. Cancer-associated thrombosis. Disease-a-Month 62 (2016), 5, 121–158.
[22]
AY. Lee, MN. Levine, G. Butler, et al. Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J Clin Oncol. 2006; 24 (9): 1404–1408.
[23]
M.-A. Sevestre, et al. Compliance with recommendations of clinical practice in the management of venous thromboembolism in cancer: The CARMEN study. J Mal Vasc39, 3, 2014, 161–168.
[24]
GT. Gerotziafas, I. Elalamy. Risque thromboembolique en oncologie: réalités, actualités et perspectives. Bull Cancer 103, 9, 2016, 764–775.
[25]
AA. Khorana, GC. Connolly. Assessing Risk of Venous Thromboembolism in the patient with cancer. 2009; (27): 4839-47.
[26]
L. Drouet. Thromboembolic risk associated with use of angiogenesis inhibitors used for the treatment of cancers. Pathologie-Biologie. 2008; (56): 195-204.
[27]
F. Elice. Thrombosis associated with angiogenesis inhibitors. Best Practice and Research Clinical Haematology. 2009; (22): 115-128.
[28]
M. Chavez-Macgregor, et al. Complications associated with erythropoietin-stimulating agents in patients with metastatic breast cancer: A Surveillance, Epidemiology, and End Results-Medicare Study. Cancer 2011; 117: 3641–9.
[29]
I. Marie, H. Levesuque, N. Cailleux, E. Primard, et al. Les thromboses veineuses profondes des membres. A propos de 49 cas. Rev Méd Interne. 1998; (19): 399-408.
[30]
P. Prandoni, P. Polistena, et al. Upper-extremity deep vein thrombosis. Risk factors, diagnosis, and complications. Arch Intern Med. 1997; (157): 57–62.
[31]
P. Prandoni, AW. Lensing, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100: 3484-8.
[32]
SR. Deitcher, CM. Kessler, et al. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180 day period. Clin Applied Thromb Hemost 2006; (12): 389-96.
[33]
RD. Hull, GF. Pineo, et al. Long term low-molecular-weight heparin versus usual care in proximal vein thrombosis patients with cancer. Am J Med 2006; (119): 1062-72.
[34]
AY. Lee, MN. Levine, RI. Baker, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; (349): 146-53.
[35]
G. Meyer, Z. Marjanovic, et al. comparison of Low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002; (162): 1729-35.
[36]
ML. Louzada, H. Majeed, PS. Wells. Efficacy of Low-molecular-weight heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials. Thromb Res 2009; (123): 837-44.
[37]
P. Mismetti, JM. Baud, F. Becker, et al. Guidelines for good clinical practice: prevention and treatment of venous thromboembolism in medical patients. J Mal Vasc2010; (35): 127-136.
[38]
D. Farge, L. Bosquet, D. Kassab-Chahmi, et al. 2008 French national guidelines for the treatment of venous thromboembolism in patients with cancer: report from the working group. Crit Rev Oncol Hematol 2010; (73): 31-46.
[39]
C. Kearon, SR. Kahn, G. Agnelli, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; (133): 454S-545S.
[40]
P. Debourdeau, et al. 2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: report from the working group. Ann Oncol. 2009; (20): 1459-71.
[41]
R. Ihaddadene, G. Le Gal, A. Delluc, M. Carrier. Dose escalation of low molecular weight heparin in patients with recurrent cancer-associated thrombosis. Thromb Res 2014; 134: 93-5.
[42]
L. Geffray. Actualités en thrombose et cancer. La revue de médecine interne 32 (2011) 265–267.
[43]
D. Farge, C. Durant, S. Villiers, et al. G. Lessons from French National Guidelines on the treatment of venous thrombosis and central venous catheter thrombosis in cancer patients. Thromb Res, 2010; 125: 108-16.
[44]
S. Villiers. La pratique et le traitement des thromboses de cathéter au cours du cancer. Journal des Maladies Vasculaires (2015) 40, 284-291.
[45]
A. Elias, P. Debourdeau, et al. Traitement curatif de la maladie thromboembolique veineuse et prise en charge des thromboses veineuses sur cathéter chez les patients atteints de cancer. Presse Med. 2009; 38: 220–230.
[46]
C. Kearon, EA. Akl, J. Ornelas, A. Blaivas, D. Jimenez, H. Bounameaux, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest 2016; 149: 315-52.
[47]
Es N. Van, M. Coppens, S. Schulman, S. Middeldorp, HR. Buller. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014; 124: 1968‑75.
[48]
M. Franchini, et al, Cancer-associated thrombosis: investigating the role of new oral anticoagulants, Thromb Research 135, 5, 2015, 777–781.
[49]
S. Noble, J. Sui. The treatment of cancer associated thrombosis: does one size fit all? Who should get LMWH/warfarin/DOACs? Thrombosis Research 140S1 (2016) S154–S159.
[50]
S. Noboa, D. Mottier, E. Oger. Estimation of a potentially preventable fraction of venous thromboembolism: a community based prospective study. J thromb Haemost 2006; (4): 2720-2.
[51]
I. Mahe, J. Chidiac. Cancer et récidive thromboembolique veineuse: non-respect des recommandations de traitement. Bull Cancer 2014; 101: 295-301.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186